Overview
If you've been on a GLP-1 medication for a while and the scale has slowed — or your insurance, your side effects, or your budget is forcing a change — you've probably asked the question: should I switch to the other one? New research presented this week finally puts real numbers behind the answer. A Cleveland Clinic study of 20,486 patients, presented at ObesityWeek 2026 on November 15 and published in the journal eClinicalMedicine, compared five different paths patients took after starting semaglutide or tirzepatide — and found that switching between the two medications was linked to about 16% total body weight loss over two years, substantially more than staying on the original drug, and four times more than stopping treatment altogether.
Here's what the study showed, which direction of switch worked better, and how to think about it if you're weighing a change in your own treatment.

